A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis

Trial Profile

A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Prezalumab (Primary)
  • Indications Arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Mar 2018 Results assessing safety, efficacy and immunogenicity published in the Arthritis and Rheumatology
    • 17 Jun 2017 Primary endpoint (Lupus Arthritis Response Rate) has not been met as per the results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top